Drug Profile
Research programme: broad spectrum anticonvulsants - Johnson & Johnson
Alternative Names: JNJ-26990990Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Diabetes mellitus; Epilepsy; Major depressive disorder; Metabolic disorders; Migraine; Neuropathic pain; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Epilepsy in USA